Indacaterol and Glycopyrronium bromide

Interactions

Indacaterol and Glycopyrronium bromide interacts in the following cases:

Severe renal impairment, end-stage renal disease

In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk. These patients should be monitored closely for potential adverse reactions.

Severe hepatic impairment

There are no data available for the use of indacaterol/glycopyrronium bromide in patients with severe hepatic impairment, therefore caution should be observed in these patients.

Urinary retention

No data are available in patients with urinary retention, therefore indacaterol/glycopyrronium bromide should be used with caution in these patients.

Narrow-angle glaucoma

No data are available in patients with narrow-angle glaucoma, therefore indacaterol/glycopyrronium bromide should be used with caution in these patients.

Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using indacaterol/glycopyrronium bromide should any of these signs or symptoms develop.

Pregnancy

There are no data from the use of indacaterol/glycopyrronium bromide in pregnant women available. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant exposures.

Indacaterol may inhibit labour due to a relaxant effect on uterine smooth muscle. Therefore, indacaterol/glycopyrronium bromide should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.

Nursing mothers

It is not known whether indacaterol, glycopyrronium and their metabolites are excreted in human milk. Available pharmacokinetic/toxicological data have shown excretion of indacaterol, glycopyrronium and their metabolites in the milk of lactating rats. The use of indacaterol/glycopyrronium bromide by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant.

Carcinogenesis, mutagenesis and fertility

Fertility

Reproduction studies and other data in animals do not indicate a concern regarding fertility in either males or females.

Effects on ability to drive and use machines

This medicinal product has no or negligible influence on the ability to drive and use machines. However, the occurrence of dizziness may influence the ability to drive and use machines.

Adverse reactions


The presentation of the safety profile is based on the experience with indacaterol/glycopyrronium bromide and the individual active substances.

Summary of the safety profile

The safety experience with indacaterol/glycopyrronium bromide was comprised of exposure of up to 15 months at the recommended therapeutic dose.

Indacaterol/glycopyrronium bromide showed similar adverse reactions to the individual components. As it contains indacaterol and glycopyrronium, the type and severity of adverse reactions associated with each of these components may be expected in the combination.

The safety profile is characterised by typical anticholinergic and beta-adrenergic symptoms related to the individual components of the combination. Other most common adverse reactions related to the medicinal product (at least 3% of patients for indacaterol/glycopyrronium bromide and also greater than placebo) were cough, nasopharyngitis and headache.

Tabulated summary of adverse reactions

Adverse reactions detected during clinical trials and from post-marketing sources are listed by MedDRA system organ class (Table). Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).

Adverse reactions:

Adverse reactions Frequency category
Infections and infestations
Upper respiratory tract infectionVery common
NasopharyngitisCommon
Urinary tract infectionCommon
Sinusitis Common
Rhinitis Common
Immune system disorders
Hypersensitivity Common
Angioedema2 Uncommon
Metabolism and nutrition disorders
Hyperglycaemia and diabetes mellitus Common
Psychiatric disorders
Insomnia Uncommon
Nervous system disorders
Dizziness Common
Headache Common
ParaesthesiaRare
Eye disorders
Glaucoma1 Uncommon
Cardiac disorders
Ischaemic heart disease Uncommon
Atrial fibrillationUncommon
Tachycardia Uncommon
PalpitationsUncommon
Respiratory, thoracic and mediastinal disorders
Cough Common
Oropharyngeal pain including throat irritation Common
Paradoxical bronchospasm Uncommon
Dysphonia2 Uncommon
EpistaxisUncommon
Gastrointestinal disorders
Dyspepsia Common
Dental cariesCommon
GastroenteritisUncommon
Dry mouthUncommon
Skin and subcutaneous tissue disorders
Pruritus/rash Uncommon
Musculoskeletal and connective tissue disorders
Musculoskeletal pain Uncommon
Muscle spasm Uncommon
MyalgiaUncommon
Pain in extremityUncommon
Renal and urinary disorders
Bladder obstruction and urinary retention Common
General disorders and administration site conditions
Pyrexia1 Common
Chest pain Common
Oedema peripheral Uncommon
Fatigue Uncommon

1 Adverse reaction observed with indacaterol/glycopyrronium bromide, but not with the individual components.
2 Reports received from post-marketing experience; frequencies calculated, however, on the basis of clinical trial data.

Description of selected adverse reactions

Cough was common, but usually of mild intensity.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.